Aim: To evaluate the achievement of metabolic risk factor targets and influencing factors in ACS patients with diabetes during the 12 months after discharge.
Methods: We retrospectively analyzed data from the Chinese Cardiovascular Association database-iHeart Project. Patients who were hospitalized with a diagnosis of ACS between 2014 and 2021 and who had at least one measurement record of LDL-C, BP, or HbA within 12 months after discharge were included. We further stratified patients by diabetes status and analyzed the correlation between clinical characteristics, measurement strategy, and achievement of targets.
Results: Diabetes was identified in 1,027 (27.5%) of the eligible patients. The proportions of patients with diabetes achieving targets of LDL-C, BP, and HbA levels were 42.4%, 61.5%, and 43.7%, respectively. However, combined achievement rate was significantly lower in patients with diabetes than patients without diabetes (16.6% vs. 26.6%). Patients with diabetes who underwent the first measurement within three months or had ≥3 measurements within 12 months were positively associated with achieving combined targets.
Conclusions: The achievement of multifactorial targets among patients with ACS is suboptimal, particularly among patients with concomitant diabetes. The optimal measurement strategy post-discharge is essential for improving the comprehensive management of metabolic risk factors in ACS patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843988 | PMC |
http://dx.doi.org/10.5334/gh.1400 | DOI Listing |
ACS Appl Bio Mater
March 2025
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Lucknow 226025, India.
Multidrug resistance (MDR) infectious wounds are a major concern due to drug resistance, leading to increased patient morbidity. Lichenysin (LCN), a lipopeptide and biosurfactant obtained from certain strains of , has demonstrated an excellent antimicrobial property. The present study focuses on the fabrication and comprehensive evaluation of LCN-incorporated poly(vinyl alcohol) (PVA)/polycaprolactone (PCL)-based nanofiber scaffolds using an electrospinning technique as a potential wound healing biomaterial for the treatment of MDR infectious wounds in diabetic rats.
View Article and Find Full Text PDFJ Clin Lipidol
February 2025
Fatty Acid Research Institute, Sioux Falls, SD, USA (Drs Tintle, Marchioli, and Harris); Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA (Dr Harris).
Background: Accurate predictive tools are crucial for identifying patients at increased risk for atherosclerotic cardiovascular disease (ASCVD). The Pooled Cohort Equation (PCE) is commonly used to predict 10-year risk for ASCVD, but its accuracy remains imperfect.
Objective: This study examined the extent to which the omega-3 index (O3I; the proportion of eicosapentaenoic acid+docosahexaenoic acid in erythrocyte membranes) improved the predictive capability of PCE.
ESC Heart Fail
March 2025
Department of Musculoskeletal Ageing and Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Aims: Malnutrition is increasingly recognized as a significant factor influencing the clinical outcomes of patients with heart failure (HF). Diabetes exacerbates risks like hospitalizations and mortality due to cardiovascular complications. The aim of this study was to explore the association of malnutrition with diabetes and its prognostic impact on all-cause and cardiovascular mortality in patients with HF, using the nutritional assessment tools, controlling nutritional status (CONUT) score and geriatric nutritional risk index (GNRI).
View Article and Find Full Text PDFCirc J
March 2025
Department of Cardiovascular Medicine, Shinshu University School of Medicine.
Background: The EMPA-REG OUTCOME trial confirmed empagliflozin reduced mortality and heart failure hospitalization risk. These findings raised the possibility that empagliflozin may modulate cardiac autonomic function in patients with type 2 diabetes (T2D).
Methods And Results: The EMPYREAN study was a prospective randomized open-label assessor-blinded multicenter investigation of patients with T2D without prior antidiabetic therapy with sodium-glucose cotransporter 2 or dipeptidyl peptidase 4 inhibitors.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!